---
schema_version: "secwatch.filing_event.v1"
accession: "0001601485-23-000057"
form_type: "8-K"
ticker: "ELTX"
cik: "0001601485"
company_name: "Elicio Therapeutics, Inc."
filed_at: "2023-09-07T23:59:59+00:00"
generated_at: "2026-06-10T22:50:34.069010+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Elicio Therapeutics receives $2.6M grant from GI Research Foundation for two cancer vaccines

## Summary
- Grant awarded on Sept 7, 2023, adds to $2.8M received in Sept 2022 from GIRF.
- Funds will advance ELI-007 (mutant BRAF-peptide) and ELI-008 (p53 hotspot mutation-peptide) vaccines.
- Vaccines use Elicio's AMP lymph node-targeting platform; CMC, regulatory, and clinical prep underway.
- BRAF V600E mutations seen in 40% melanoma, 10% colon, 2% lung; p53 mutations in ~30% solid tumors.
- Non-dilutive funding supports IND planning and initial patient clinical assessment.

## SEC filing metadata
- accession: 0001601485-23-000057
- form_type: 8-K
- ticker: ELTX
- cik: 0001601485
- company_name: Elicio Therapeutics, Inc.
- filed_at: 2023-09-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601485/000160148523000057/0001601485-23-000057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601485/000160148523000057/angn-20230907.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601485-23-000057
- JSON: https://secwatch.observer/filing/0001601485-23-000057.json
- Plain text: https://secwatch.observer/filing/0001601485-23-000057.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.